Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Trial Parameters
Brief Summary
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
Eligibility Criteria
Inclusion Criteria: * Histologically or clinically confirmed diagnosis of HCC. * Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy. * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. * With Child-Pugh 5\~7 scores. Exclusion Criteria: * Concurrent with other malignancies within 5 years. * Incomplete medical data. * Follow-up time less than 3 months.